Compare FRT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | BMRN |
|---|---|---|
| Founded | 1962 | 1996 |
| Country | United States | United States |
| Employees | 320 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.4B |
| IPO Year | N/A | 1999 |
| Metric | FRT | BMRN |
|---|---|---|
| Price | $115.52 | $52.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 18 |
| Target Price | ★ $112.08 | $88.22 |
| AVG Volume (30 Days) | 716.9K | ★ 1.6M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $6.10 | $15.02 |
| Revenue Next Year | $4.64 | $12.23 |
| P/E Ratio | ★ $22.54 | $100.07 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $89.99 | $50.76 |
| 52 Week High | $117.22 | $66.28 |
| Indicator | FRT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 41.02 |
| Support Level | $103.41 | $52.06 |
| Resistance Level | N/A | $56.52 |
| Average True Range (ATR) | 1.72 | 1.70 |
| MACD | 0.25 | 0.04 |
| Stochastic Oscillator | 77.47 | 6.12 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 104 properties, which includes 28.8 million square feet of retail space and 2,700 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.